This study investigated the loss of resistance of multidrug resistant (MDR)Pseudomonas
INTRODUCTION
Pseudomonas aeruginosa is a highly invasive and toxigenic aerobic Gram negative bacterium. It is nonsporing, non-capsulated and usually motile with the help of one or two flagella. The organism readily grows over a wide range of temperature and media. The reasons for the preeminence of this microorganism as a human pathogen range from its adaptability, its innate resistance to many antibiotics, disinfectants and its virulence factors (Aendekerk et al., 2005) . The organism is a danger and threat to patients with cystic fibrosis or AIDS and other *Corresponding author. E-mail: fesdotaj@yahoo.com or dafotaj@hotmail.com.
immune disorders as well as those requiring long-term hospitalization. P. aeruginosa is an opportunistic pathogen with innate resistance to many antibiotics and disinfectants (Shahid et al., 2003) . The microorganism is physiologically versatile and flourishes as a saprophyte in multiple environments including sinks, drains, respirators, humidifiers, and disinfectant solutions (Govan and Deretic 1996) . P. aeruginosa is notorious for its resistance to antibiotics as it maintains antibiotic resistance plasmid (R) factor (Radi and Rahman, 2010) . These plasmids are transmissible to sensitive bacteria which make them acquire resistance to antibiotics and have the ability to undergo recombination through conjugation, transformation and transduction. Multidrug active efflux systems have recently been recognized in a number of bacteria as efficient mechanisms of resistances in P. aeruginosa by which antibiotics are expelled from the cells by membrane transporter proteins, the so called drug efflux pumps (Lomovskaya et al., 2001) .
Infections due to P. aeruginosa are seldom encountered in healthy adults. The organism has become increasingly recognized as the etiological agent in a variety of serious infections in hospitalized patients especially those with impaired immune defenses (Neu, 1993) . The indiscriminate use of antimicrobial drugs parti-cularly in hospitalized patients leads to the suppression of drug susceptible organisms in the gut flora and favors the persistence and growth of resistant bacteria including P. aeruginosa. The closed environment of hospitals favors the transmission of such resistant strains through personnel, fomites and by direct contact (Melnick and Adelberg, 1998) .
P. aeruginosa is the most common and lethal pathogen responsible for urinary tract infections (UTI), ventilator associated pneumonia in intubated patients with directly attributable deaths reaching 38% (Mansouri et al., 2011) . Multidrug resistant (MDR) P. aeruginosa is found to be resistant to a very large number of antibiotics (Bonomo and Szabo, 2006; Manikandan et al., 2011) . Resistance may be due to interplay of various interactions including beta-lactamases, mutations, decreased permeability and the activities of efflux pumps (Defez et al., 2004; Abdi-Ali et al., 2007) and presence of drug resistant plasmids (Ranjbar et al., 2007) .
P. aeruginosa is a serious threat in clinical medicine since most isolates are resistant simultaneously to many antibiotics at very high levels (Mukherjee et al., 2011) . Elimination of these resistance markers (RM) by known pharmacological compounds would be advantageous in successful therapeutic control of various infections caused by this pathogen (Mukherjee et al., 2011) .
There are a number of reports demonstrating the ability of various chemical and physical agents to increase the rate of loss of plasmid DNA from bacteria (Sonstein and Baldwin, 1972; Stanier, 1984; Otajevwo, 2012) . Antibiotics such as mitomycin, rifampicin, novobiocin and flavophospholipol as well as DNA intercalating dyes (such Otajevwo and Okungbowa 25 (such as acridine orange, ethidium bromide, acriflavine and ascorbic acid) have been shown to cure many plasmids (Ramesh et al., 2000) . Acridine orange has been shown to cure F-plasmids from Escherichia coli and it is suggested that this dye interfers with plasmid replication, stimulating the entire plasmid loss (Salisbury et al., 1972) . It has also been reported that acridine orange and ethidium bromide are better curing agents for Pseudomonas cepacia than sodium dodecyl sulphate (SDS) and elevated temperature (Kumar and Surendran, 2006) . Stanier (1984) reported that the elimination of plasmids by dyes and other agents reflects the ability of such agents to inhibit plasmid replication at a concentration that does not affect the chromosome. Acridine orange, ethidium bromide, mitomycin and SDS failed to cure the plasmid of Pseudomonas putida, though the phenotypic characteristics changed and the plasmid was cured at a frequency of 2.63% when acridine orange and elevated temperature (40°C) were used together (Stanier, 1984) . Ingram et al. (1972) found that drug resistance of P. aeruginosa could be eliminated by treatment with SDS and Pattnakik et al. (1995) reported that acridine orange could not affect P. aeruginosa due to impermeability of its cell wall while ethidium bromide and SDS cured antibiotic resistance plasmid at a concentration of 1 to 2% and 700 to 3000 µg/ml for SDS and ethidium bromide, respectively. Al-Amar et al. (1999) treated an isolate of P. aeruginosa with 1000 µg/ml dilution of acridine orange and reported that there were no cured cells as the plasmid profile of cured cells was the same as that of untreated samples with a conclusion that acridine orange had no effect on P. aeruginosa as a curing agent.
Treatments that increase frequency of elimination of plasmids will certainly enhance sensitivity (effectiveness) of antibiotics in situ. There is dearth of literature on antibiotic sensitivity improvement (through loss of RM) using dilutions of chemical agents such as acridine orange. Hence, the aim of this work was to study the RM loss of MDR P. aeruginosa strains after treatment with clinical dilutions of acridine orange with the following objectives:
(1) Determine the sensitivity profile of P. aeruginosa strains (from selected diseased sites of the human body) before treatment with dilutions of acridine orange after incubation for 24 h at 37°C. (2) Determine the distribution of multidrug RM among the selected pathogenic strains of P. aeruginosa. (3) Determine P. aeruginosa strains that showed ≤50.0% loss of their RM after 0.35 µg/ml acridine orange dilution treatment and incubation at 37°C for 24 h. (4) Determine P. aeruginosa strains that showed ≤50.0% loss of their RM after 0.55, 0.75 and 0.95 µg/ml acridine orange dilution treatments and incubation at 37°C for 24 h. 
MATERIALS AND METHODS

Sampling
Five pure axenic strains of P. aeruginosa coded PA1 to PA5 were obtained from the Medical Microbiology Department of University of Benin Teaching Hospital, Edo State, Nigeria. Bacterial pathogens which were isolated from ear swab, urethral swab, tracheal (throat) swab, wound swab, and mid stream urine samples, respectively, were inoculated aseptically (in pure form), on sterile nutrient agar slants and incubated at 37°C for 24 h. All strains were appropriately labeled.
Processing of samples
Colonies from resulting stocked cultures were re-confirmed by subculturing them on sterile nutrient agar (LabM, UK), MacConkey agar (LabM, UK) and Blood agar plates and inoculated plates were incubated at 37°C for 24 h. Purity test was done on all prepared agar plates before use to guarantee their sterility. Resulting colonies were inoculated on the selective medium centrimide agar and incubated appropriately.
Finally, oxidase test and gram staining were done on resulting colonies according to scheme provided by Cowan and Steel (1993) . Colonies were stocked on sterile nutrient agar slants and kept at 4°C in the refrigerator for further use. The set up was appropriately labeled. All isolated bacterial pathogens were subjected to antibiotics sensitivity testing before treatment with dilutions of acridine orange.
Antibiotic sensitivity testing
Antibiotic sensitivity testing on each of the five pure strains of P. aeruginosa was carried out using the disc diffusion method on sterile Mueller-Hinton agar (MHA) plates (Bauer et al., 1966) . A loop full of each colony was picked aseptically using a flamed wire loop and placed in the centre of sterile MHA plates. This was then spread all over the plates applying the caution of not touching the edges of the plates. The seeded plates were allowed to stand for about 2 min to allow the agar surface to dry. A pair of forceps was flamed and cooled and used to pick antibiotic multidisc (Abitek, Liverpool) containing augmentin (30 µg), ofloxacin (5 µg), gentamicin (10 µg), nalidixic acid (30 µg), nitrofurantoin (200 µg), cotrimoxazole (25 µg), amoxicillin (25 µg) and tetracycline (25 µg). Discs were placed at least 22.0 mm from each other and 14.0 mm from the edge of the plate (Ochei and Kolhatkar, 2008) . Antibiotics discs were selected on the basis of their clinical importance and efficacy on P. aeruginosa. Plates were allowed to stand for 10 min tunes before incubation (Mbata, 2007) .
The plates were incubated at 37°C for 24 h. A reference control strain of P. aeruginosa NCTC was inoculated in the same way on another plate with the same antibiotic discs and incubated at the same temperature and time. At the end of incubation, the diameters of the zones of inhibition from one edge to the opposite edge were measured to the nearest millimeter using a transparent ruler (Byron et al., 2003) . Strains that showed resistance against three antibiotics and above were termed multiple drug resistant strains (Jan et al., 2002) and were noted and used further.
Preparation of dilutions of acridine orange
For treatment of MDR P. aeruginosa strains, sub-clinical acridine orange concentrations of 0.35, 0.55, 0.75 and 0.95 µg/ml were used. These concentrations (dilutions) were chosen in line with non-toxic laboratory concentrations of 0.25 to 1.0 µg/ml prescribed by Wurmb-Schwark et al. (2006) for ethidium bromide which have been reported to possess curing potentials. Hence, acridine orange dilutions of 0.35, 0.55, 0.75 and 0.95 µg/ml were prepared using RV/O where stock or original concentration of acridine orange used was 1.0 mg/ml or 1000 µg/ml. To obtain 0.35 µg/ml dilution therefore, 0.14 ml of stock reagent was added to sterile 9.86 ml of Mueller-Hinton broth. To obtain 0.55 µg/ml acridine orange dilution, 0.11 ml stock acridine orange solution was added to sterile 19.78 ml Mueller-Hinton broth. Also to obtain 0.75 µg/ml dilution, 0.30 ml stock solution was added to sterile 19.70 ml Mueller-Hinton broth and 0.38 ml stock solution of acridine orange was added to sterile 19.61 ml of Mueller-Hinton broth to obtain 0.95 µg/ml dilution. All dilutions were effected in sterile universal bottles containing sterile 20.0 ml of Mueller-Hinton broth each.
Growing broth culture of MDR P. aeruginosa strains
A colony of each MDR strain was aseptically picked from its slant stock culture using flamed and cooled wire loop and inoculated into sterile 10 ml Mueller-Hinton broth. Inoculated broths were incubated at 37°C for 18 h. The resulting turbid broth culture was then diluted according to a modified method of Shirtliff et al. (2006) . Using a sterile pipette, 0.1 ml of broth culture was mixed with 99.9 ml (1:200 dilution) of sterile Mueller-Hinton broth. This was properly mixed and was used as working inoculum and should contain 10 5 to 10 6 organisms, which was used within 30 min (Ochei and Kolhatkar, 2008) .
Treatment of MDR pathogenic strains with prepared acridine orange dilutions
The treatment of MDR P. aeruginosa pathogenic strains with the prepared dilutions of acridine orange was done according to a modified method of Byron et al. (2003) . Using a sterile pasteur pipette, 0.5 ml aliquot of each diluted overnight broth culture of MDR pathogen was added to 4.5 ml sterile molten Nutrient agar. The various prepared dilutions (one at a time) of acridine orange were then added in 0.5 ml volume. The set up was properly mixed and labeled. The set up for each dilution was then poured on top of sterile hardened or set 2% Nutrient agar plates and left to set. The same antibiotic multidisc used before treatment were then picked (using flamed and cooled pair of forceps) and impregnated on the set agar overlay plates. Plates were incubated at 37°C for 24 h. Measurement of diameters of zones of inhibition was taken and recorded (NCCLS, 2000) .
Determination of MIC of gentamicin after acridine orange treatment
Serial doubling dilutions of gentamicin, the antibiotic to which a P. aeruginosa strain (isolated from mid stream urine) recorded more than 50.0% RM loss was carried out. The antibiotic being used for this assay was sterilized by filtration before use. Sterile test tubes, numbering 13 were set up on a test tube rack and labeled 1 to13.
Using a sterile pipette, 1 ml of diluted broth was dispensed into tubes 2 to 10, 11 and 13. Into tube 12, 2.0 ml of diluted broth culture was pipetted. Tube 11 was the inoculum control, tube 12 was the broth control and 13 was the drug control. Into tubes 1, 2 and 13, 1 ml of the working antibiotic solution was pipetted. Serial doubling dilutions of antibiotic solution were separately prepared in Table 1 . Sensitivity profile of P. aeruginosa strains before treatment with subclinical concentrations of acridine orange after incubation at 37°C for 24 h. nutrient broth to get reducing concentrations of the antibiotic using 100 to 0.4 µg/ml as a standard for MIC assay (Ochei and Kolhatkar, 2008) . All tubes were incubated at 37°C for 18 h. Turbidity (cloudiness) in the growth medium indicated growth. Tube 11 showed turbidity and tubes 12 and 13 showed no growth. The lowest concentration showing no growth was the MIC of the antimicrobial agent as effective against P. aeruginosa strains. All MIC results before and after treatment with dilutions of acridine orange were recorded accordingly. Strains PA 1 , PA 2, PA 4 and PA 5 isolated from ear swab, urethra swab, wound swab and mid stream urine, respectively were each resistant to 6 (75.0%) of the total antibiotics tested. Interestingly, all four P. aeruginosa strains were each sensitive to ofloxacin and gentamicin. Only strain PA 3 (isolated from tracheal swab) resisted 8 (100.0%) or the entire antibiotics used.
Strain code
RESULTS
In Table 3 , the percentage loss of RM due to 0.33 µg/ml acridine orange curing effect is shown. Loss of 50% and above of RM was recorded for P. aeruginosa strains PA 1 (with 78.5% loss of resistance to ofloxacin), PA 2 (with 80.0 and 61.5% loss of resistance to ofloxacin and gentamicin, respectively), PA 4 (with 50.0 and 58.3% loss of resistance to ofloxacin and gentamicin, respectively). PA 5 strain recorded 60.0% loss of resistance to gentamicin. With the exception of strain PA 3, all strains maintained 100.0% resistance to 6 (75.0%) of the antibiotics used which included: augmentin, nalidixic acid, nitrofurantoin, cotrimoxazole, amoxicillin and tetracycline after treatment with 0.35 µg/ml acridine orange. Strain PA 3 resisted 8 (100.0%) of the antibiotics used. Table 4 shows percentage loss of RM due to 0.55 µg/ml curing effect of acridine orange. Loss of 50% and above of RM was recorded for P. aeruginosa strains PA 1 (with 50.0% loss to gentamicin), PA 2 (with 160.0 and 76.9% loss to ofloxacin and gentamicin respectively), PA 4 (with 83.3% loss to gentamicin) and PA 5 with 58.8 and 180.0% loss of RM of ofloxacin and gentamicin, respectively. Strain PA 3 maintained 100.0% resistance to 8 (100.0%) of the antibiotics used while the remaining four strains maintained 100.0% resistance to 6 (75.0%) of the antibiotics used after treatment with 0.55 µg/ml acridine orange.
Data on 50% and above reduction in RM in P. aeruginosa strains after treatment with 0.75 µg/ml acridine orange are shown in Table 5 . P. aeruginosa strains PA 1 and PA 5 recorded 50 and 120.0% loss, respectively in RM to gentamicin. Strain PA 2 recorded less than 35.0% loss in RM to ofloxacin and gentamicin. Strains PA 4 and PA 5 each recorded less than 20% loss in resistance to ofloxacin. P. aeruginosa strain PA 3 showed 100.0% resistance to 8 (100.0) of drugs used, while other strains recorded 100.0% resistance to augmentin and tetracycline. There were slight losses in RM for nalidixic acid, nitrofurantoin, cotrimoxazole and amoxicillin as recorded for PA 1 , PA 4 and PA 5 .
The effect of 0.95 µg/ml acridine orange treatment of the P. aeruginosa strains on the selected antibiotics is shown in Table 6 . Only P. aeruginosa strain PA 5 recorded 120.0% loss in RM gentamicin. Strain PA 1 showed less than 25.0% loss of ofloxacin and gentamicin. Strain PA 2 recorded less than 10.0% and less 40.0% loss of ofloxacin and gentamicin respectively. Strain PA 4 showed less than 10.0% loss to gentamicin while PA 5 recorded 120.0% loss in RM to gentamicin. Strains PA 1 , PA 2 , PA 4 and PA 5 recorded 100.0% resistance loss to 6 (75.0%) of the antibiotics used after acridine orange treatment, while strain PA 3 showed 100.0% loss to 8 (100.0%) of the drugs used for the susceptibility testing.
Presented in Table 7 , is the effect of subclinical dilutions of acridine orange on the MIC of gentamicin as it inhibited the growth of the growth of Table 4 . P. aeruginosa strains that showed ≤50.0% loss of their resistance markers after treatment with 0.55 µg/ml dilution of acridine orange and incubation at 37°C for 24 h. MDR P. aeruginosa strain PA 5 (isolated from midstream urine) or the effect of the dilutions in RM reduction or otherwise, of PA 5 strain. Whereas 0.35 µg/ml acridine orange dilution caused a two-fold (5.0 µg) reduction in gentamicin MIC (which is 10 µg), 0.55 µg/ml dilution caused a four-fold (2.5 µg) reduction. Both 0.75 and 0.95 µg/ml acridine orange dilutions recorded no effect (no change) in the MIC of gentamicin. In Table 8 , the summary and distribution of 50.0% and above loss in RM is presented. P. aeruginosa strains PA 2 and PA 5 recorded 160.0 and 58.8% loss in RM, respectively to ofloxacin with mean loss of 54.7±37.6% after treatment with 055 µg/ml acridine orange. This was followed by mean loss of 52.1±18.6% to ofloxacin after treatment with 0.35 µg/ml acridine orange. Strains PA 1 , PA 2 , PA 4 and PA 5 recorded 50.0, 76.9, 83.3 and 180.0% loss in RM, respectively to gentamicin with mean loss of 97.6±28.3% after treatment with 0.55 µg/ml acridine orange Table 6 . P. aeruginosa strains that showed ≤50.0% loss of their resistance markers after treatment with 0.95 µg/ml dilution of acridine orange and incubation at 37°C for 24 h. No change ----
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Gentamicin was chosen for MIC Assay because it was one of the two antibiotics that recorded ≤50.0% reduction in resistance markers. PA5 (P. aeruginosa isolated from midstream urine) was selected and used for MIC assay on the basis of organism that showed up to ≤50.0% reducti on in resistance markers for all four dilutions. Table 8 . Distribution of ≤50.0% loss of resistance markers among multidrug resistant P. aeruginosa strains after treatment with 0.35, 0.55, 0.75 and 0.95 µg/ml dilutions of acridine orange. orange. This was followed by mean loss of less than 50.0% to gentamicin after treatment with 0.75 µg/ml acridine orange. This was followed by mean losses of 45.0±15.0, 42.5±12.1 and 30.0±16.1% all to gentamicin after treatment with 0.35, 0.75 and 0.95 µg/ml, respectively.
MDR strain
The highest and lowest mean loss of RM therefore, were 97.6±28.3 and 30.0±16.1% after treatments with 0.55 and 0.95 µg/ml, respectively and both to gentamicin. There was no reduction in RM to ofloxacin after 0.75 and 0.95 µg/ml acridine orange treatments. In all, mean loss of 50.0% or more of RM was recorded after treatment with 0.35 µg/ml (52.1±18.6%) and 0.55 µg/ml (97.6±28.3%) to gentamicin.
DISCUSSION
The antibiotics susceptibility profile of all five strains of P. aeruginosa before acridine orange treatment in this study showed that the five strains were sensitive to ofloxacin and gentamicin with mean±SE zones of inhibition of 14.6±9.5 and 8.4±4.4 mm, respectively. This means only 2 (25.0%) of the antibiotics recorded positive reactions when tested on the pathogenic organisms. By extension, this also implies that 6 (75.0%) of the antibiotics were completely resisted by the five P. aeruginosa strains. This is rather alarming as findings confirm the MDR nature of P. aeruginosa as reported by earlier authors (Radi and Rahman, 2010; Mukherjee et al., 2011) . Findings in this study (in terms of antibiotic sensitivity profile) is disturbing because it ostensibly suggests that infections or diseases caused by MDR P. aeruginosa in the study environment can be treated successfully with only ofloxacin or gentamicin or a combination of both. This place the low income patients at a serious disadvantage as they may not be able to afford ofloxacin which is expensive and which showed almost twice sensitivity reaction compared with gentamicin.
Particularly worrisome, is the total resistance against augmentin, amoxicillin and cotrimoxazole because these drugs are used routinely to treat a myriad of human diseases. This same worry with particular reference to augmentin has been expressed by some authors (Oluremi et al., 2011) . It was not clear as to whether the site from where the pathogens were isolated had any direct or indirect effect on the antibiograms of the strains as recorded in this study. However, it may be possible that pH changes or variations from site to site and presence/absence of oxygen could affect the response of P. aeruginosa (a strict aerobe) to relevant antibiotics it is exposed to in vitro.
A pathogen is MDR when it is resistant to three or more antibiotics at any given time (Jan et al., 2002) . Based on results obtained in this study, P. aeruginosa strains isolated from ear swab, urethral swab, wound swab and midstream urine were each resistant to augmentin, nalidixic acid, nitrofuratoin, cotrimoxazole, amoxicillin and tetracycline (6 drugs) representing 75.0% of the antibiotics tested. Only strain PA 3 (isolated from tracheal swab) resisted eight drugs representing 100.0% of antibiotics tested. This finding re-establishes the MDR nature of P. aeruginosa strains irrespective of the source or site from where they are isolated. The high prevalence of multiple antibiotic resistant P. aeruginosa strains in this study is a possible suggestion that very large population of P. aeruginosa organisms has been exposed to several antibiotics which is consistent with report of earlier studies (Oluremi et al., 2011 ).
Otajevwo and Okungbowa 31
Acridine orange dilutions of 0.35, 0.55, 0.75, and 0.95 µg/ml were used to treat and cure the five pathogenic strains of P. aeruginosa with the intent of reducing their RM significantly or eliminating them completely. The loss of 50 to 100% of RM after treatment with acridine orange subclinical dilutions of 0.35, 0.55, 0.75 and 0.95 µg/ml was used as the basis of establishing the curing effects of these dilutions. The use of 50% and above loss in RM as a criterion to determine the extent of plasmid curing was according to the scheme provided by Akortha et al. (2011 ). Stanier et al. (1984 reported that the elimination of plasmids by dyes and other agents reflects the ability of such agents to inhibit plasmid replication at a concentration that does not affect the chromosome.
It has been reported that acridine orange and ethidium bromide are better curing agents for P. aeruginosa than sodium dodecyl sulphate (SDS) and elevated temperature (Kumar and Surendran, 2006) . Earlier studies reported no effect of acridine orange on plasmids of P. aeruginosa (Pattnakik et al., 1995; Al-Amir et al., 1999) . Reports of some other earlier studies stated a reversion in the resistance of some multiple drug resistant strains following exposure to acridine orange (Naomi, 1978; Darini, 1996; Adeleke and Odetola, 1997) .
P. aeruginosa strain PA 1 (isolated from ear swab) recorded 78.5% loss of RM to ofloxacin after 0.35 µg/ml treatment with acridine orange. For the same strain, there was zero loss of RM to ofloxacin after 0.55, 0.75 and 0.95 µg/ml treatments with the agent. This somewhat implies that 0.35 µg/ml is a choice dilution of the agent which may enhance antibiotic sensitivity of this MDR P. aeruginosa strain of ofloxacin.
In case of strain PA 2 (isolated from urethral swab), RM losses of 80.0 and 160.0% to ofloxacin were recorded after 0.35 and 0.55 acridine orange treatments, respectively. Strain PA 4 (isolated from wound swab) recorded 50.0% loss of RM to ofloxacin after 0.35 µg/ml treatment with the curing agent. There was zero loss of RM to ofloxacin by strain PA 5 with 0.35 µg/ml treatment and 58.8% loss of RM to the same drug after 0.55 µg/ml acridine orange treatment. The mean±SE loss of RM of 52.1±18.6 and 54.7±37.6% to ofloxacin by all the MDR P. aeruginosa strains after 0.35 and 0.55 µg/ml acridine orange treatments, respectively, tends to suggest potency of either or both dilutions in the enhancement of sensitivity to ofloxacin in the course of treatment. In a related study, Otajevwo (2012) reported 0.35, 0.85 and 0.95 µg/ml dilutions of homodium (ethidium) bromide as significant enhancers of a multidrug uropathogenic Escherichia coli strain to some selected antibiotics.
Some authors have used dilutions of a non-antibiotic compound-thioridazine to reduce RM in some strains of P. aeruginosa (Mukherjee et al., 2011) . Loss of RM to gentamicin by strains PA 1 , PA 2 , PA 4 and PA 5 after 0.35 µg/ml acridine orange treatment was recorded as 0.0, 61.5, 58.3 and 60.0%, respectively with a less than 50.0% mean±SE dilution (that is 45.0±15.0%). After 0.55 µg/ml treatment with acridine orange, PA 1 , PA 2 , PA 4 and PA 5 strains showed loss of RM of 50.0, 76.9, 83.3 and 180.0%, respectively with a mean±SE percentage loss of 97.6±28.3. Acridine orange dilutions of 0.75 and 0.95 µg/ml recorded less than 45.0 and 35.0% loss of RM, respectively. These findings also suggest 0.55 µg/ml dilution and to a lesser extent, 0.35 µg/ml as potential enhancers of antibiotic sensitivity in MDR P. aeruginosa pathogens.
Sensitivity enhancement effect of the subclinical acridine orange dilutions on the minimum inhibitory concentration (MIC) of gentamicin as it affected MDR P. aeruginosa strain (isolated from midstream urine) showed a two-fold (5.0 µg) and four-fold (2.5 µg) reductions in MIC of gentamicin as recorded for 0.35 and 0.55 µg/ml acridine orange dilutions, respectively. Some authors had reported similar findings on MDR Staphylococcus aureus strains (Otajevwo and Momoh, 2013) . A fast and accurate determination of MIC can ensure optimal effective treatment of patients while at the same time avoiding over-prescription. This will save money for health care providers as well as reduce development of resistance (NCCLS, 2000; McGowan and Wise, 2001) .
In this study, the MIC of gentamicin (an aminoglycoside) which is 10 µg (based on long standing research) was reduced to 5 µg (two fold reduction) and 2.5 µg (four fold reduction) by acridine orange subclinical dilutions of 0.35 and 0.55 µg/ml, respectively as tested on a multiple resistant drug strain of P. aeruginosa isolated from the urinary tract of a patient. A similar report had been made by an author which stated that 0.35, 0.45, 0.75, 0.85 and 0.95 µg/ml dilutions of homodium bromide reduced the MIC of gentamicin to 2.5, 5, 5, 2.5 and 2.5 µg, respectively when tested on an MDR strain of uropathogenic E. coli (Otajevwo, 2012) . The implication of findings in this study is that when doses of either 0.35 or 0.55 µg/ml or both are incorporated into the manufacture of gentamicin or any other related aminoglycoside, and then administered to a patient diagnosed to be suffering from a disease caused by any MDR P. aeruginosa strain, a better result in terms of outcome (cure of the disease) may be achieved as it will require four times its concentration to function in vivo. In a related work, Kohler (2010) showed that the resistance of P. aeruginosa to tetracycline efflux was reduced from MIC 0.032 to 0.004 µg/ml (eight-fold reduction) by treatment with phenothiazine. Crowle et al. (1992) demonstrated that non-toxic concentrations of phenothiazine in the lungs achieved complete elimination of Mycobacterium tuberculosis. In a related study, some workers had reported the capacity of an aqueous methanolic plant extract-epidiosbulbin -E-Acetate (EEA) to decrease the MIC of antibiotics against MDR bacteria thus making antibiotic treatment more effective (Shiram et al., 2008) .
Conclusion
All five MDR P. aeruginosa strains used in this study showed 100.0% resistance against augmentin, nalidixic acid, nitrofurantoin, cotrimoxazole, amoxicillin and tetracycline. Fortunately, all five MDR (but one, PA 3 ) strains showed sensitivity to ofloxacin and gentamicin. This finding implies that augmentin and amoxicillin for example, which are used routinely to treat a gamut of human diseases may not yield good result in terms of curing human diseases due to MDR P. aeruginosa and therefore, their routine prescription should be discouraged. Sensitivity to ofloxacin and gentamicin on the contrary, suggests that either of the two drugs or a combination of both may proof successful in tackling human diseases due to MDR P. aeruginosa. Four of the five strains were each resistant to 6 (six) of the antibiotics tested and this qualifies them as multiple drug resistant organisms. This finding re-establishes the MDR nature of P. aeruginosa strains irrespective of source or site they are isolated from. The high prevalence of multiple antibiotic resistant P. aeruginosa strains in this study therefore is a possible suggestion that very large population of P. aeruginosa organisms has been exposed to several antibiotics (that is, drug abuse). Symptomatic and asymptomatic patients are advised therefore to desist from self medication for any justifiable reason. They should ensure drugs are taken based on prescription by a qualified doctor after proper evaluation.
Acridine orange of 0.35 and 0.55 µg/ml recorded loss of RM of 52.1±18.6 and 54.7±37.6% to ofloxacin, respectively and then loss of RM of 45.0±15.0 and 97.6±28.3% to gentamicin, respectively. This is suggestive of the potency of either or both dilutions in the enhancement of sensitivity to ofloxacin and gentamicin in the course of therapy in vivo as they may be able to eliminate drug resistance plasmids.
Finally, acridine orange dilutions of 0.35 and 0.55 µg/ml recorded two-and four-fold reductions in MIC of gentamicin, respectively when tested on a MDR strain of P. aeruginosa. Again, the aforementioned dilution if incooperated into drug regimens may produce better effect and results in terms of cure of a disease which will require four times the concentration of the new MICs to function in vivo. A decrease in the MIC of an antibiotic will make the particular antibiotic more effective in treatment of a Pseudomonas disease.
SUGGESTIONS FOR FURTHER STUDIES
The determination of resistance loss by MDR P. aeruginosa strains after treatments with 0.35, 0.55, 0.75 and 0.95 µg/ml acridine orange dilutions may not be totally convincing. It is recommended therefore, that the effects of these dilutions in the pathogens at the molecular level be probed further by carrying out plasmid profiling before and after treatment to see at what dilution(s) there is partial or total elimination of drug resistance "R" plasmid bands.
